A Whole New World of RCC: Are You Ready?
This virtual tumor board curriculum features a multidisciplinary panel presenting two patient cases and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Expert faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
RCC Treatment Strategies in a Poor-Risk Patient
Case-based EducationDid you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
Faculty: Oguz Akin, MD; Robert Motzer, MD; Elizabeth Plimack, MD, MS; Jay Raman, MD, FACS
Release Date:
Expiration Date: August 27, 2022
CME/CE is no longer available for this activity
RCC Treatment Strategies in a Favorable-Risk Patient
Case-based EducationImmune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
Faculty: Oguz Akin, MD; Robert Motzer, MD; Elizabeth Plimack, MD, MS; Jay Raman, MD, FACS
Release Date:
Expiration Date: September 17, 2022
CME/CE is no longer available for this activity
